Quickly find freely available drug and population models in our PBPK model repository.
The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.
To contribute published user compound and/or population files, upload your files here: Upload Model Files
http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full Adefovir compound in healthy volunteers. Hsueh et al evaluating the effect of renal impairment on PK of OAT substrates. 30/07/2019: The Adefovir PBPK model was submitted with the setting as Hepatocyte Clearance input in the WOMC option. To allow DDI simulations the file should be set up in the Enzyme Kinetics option by moving the Hepatocyte clearance value into the Additional Clearance (Liver) subtab under the Enzyme Kinetics section.
Brand Name(s) include: Coartem (artemether, lumefantrine), Riamet (artemether, lumefantrine)
Disease: Malaria
Drug Class: Antimalarials
Related Files: Artemether – drug partner in fixed dose combinations
Date Updated: December 2022
Absorption Model |
|
Volume of Distribution Details |
Note: Kp scalar and Kp adipose used |
Route of Elimination |
CYP3A4 (40%); non-specific hepatic metabolism (60%) |
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Updates in V19 |
|
Brand Name(s) include: Biltricide, Cysticide, Praquantel
Indication: Schistosomiasis and clonorchiasis/opisthorchiasis due to the liver flukes
Drug Class: Anthelmintic
Version: 22
Date Updated: February 2024
Absorption Model |
|
Volume of Distribution Details |
Full model (method 3) |
Route of Elimination |
|
Perpetrator DDI |
|
Validation |
|
Limitations |
|
Compound file from publication: Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations Pilla Reddy, V., Bui, K., Scarfe, G., Zhou, D., Learoyd, M. (2018). Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.1103 https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1103 Note: The file is for the tablet form (Table 5 of the paper). The UGT1A1 Ki value of 48.4 µM is currently not included in the file.
6 |